in 2003, medicaid spent $33.7 billion on drugs (19% of national spending for drugs and more than 10%...
TRANSCRIPT
-
In 2003, Medicaid spent $33.7 billion on drugs (19% of national spending for drugs and more than 10% of the Medicaid budget)Medicaid expenditures ($ billions) for outpatient prescription drugsUS$Spend doubled in 4 years 1998-2002And cancer drugs are a key driver to rising costs
-
Confirmation in Europe: Cancer drugs budgets are doubling each 4 years Costs of anticancer drugs, France:2004 = 474 Million Euros2008 = 975 Million Euros
Perrin S. Therapeutic decision making in oncology. Hospital Pharmacy Europe. 2010 (Sept/Oct);52:36-37Spend doubled in 4 years 2004-2008
Chart1
474
975
Millions of Euros
Sheet1
Millions of Euros
2004474
2008975
To resize chart data range, drag lower right corner of range.
-
The world spends more each year for cancer treatmentData: IMSGlobal spend on oncology drugs: projected for 2010-12Spend doubled in 4 years 2004-2008It is a worldwide problem
Chart1
24
29
35
42
48
52
55
60
65
Billions of US Dollars
Sheet1
YearBillions of US Dollars
200424
200529
200635
200742
200848
200952
201055
201160
201265
-
Cancer drugs are associated with cancer cures! - Timeline of novel cancer drug approvalCarin A Uyl-de Groot et al. The Economics of Improved Cancer Survival Rates: Better Outcomes, Higher Costs. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(3):283-292
-
Association of novel drugs and cancer mortalityCarin A Uyl-de Groot et al. The Economics of Improved Cancer Survival Rates: Better Outcomes, Higher Costs. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(3):283-292
-
Cost of cancer drugs by year of approvalLimits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Bach P. N Engl J Med 2009; 360:626-633Cancer drug costs rise 5x faster than other classes of medicineBach P. NEJM. 2009 Feb 7
-
Cost of treatment for metastatic colon cancer(Schrag D. NEJM. 2004;351:317-319)Cost of standard therapy has risen from $63 / 8 weeks to 30,675 / 8 weeks:500-fold rise in a decade
-
Planning for the future: what will happen to costs?USA Office of management and Budget. www.whitehouse.gov/ombmedical treatment drives cost inflation far more than the aging populationWhat is the driver for increased spending: ageing populations or medical treatment?
-
When will the health expenditure inflation bankrupt the US economy?
2% point gap: health care affordable only until 2020; over 75 years, 118.5% of real increase in per capita income devoted to health care (e.g., implausible)
1% point gap: health care is affordable until 2083; 54% of real increase in per capita income goes to health care
Michael E. Chernew, Richard A. Hirth, and David M. Cutler Increased Spending On Health Care: Long-Term Implications for The Nation. Health Affairs,September/October 2009, vol. 28, Number 5, pp. 1253- 1255.
A small effort to control the growth of expenditures NOW can sustain health service development to 2083!Failure to control expenditure now risks collapse within a decade
-
What are policy-makers trying to do?
-
What are policy-makers trying to do?Protect and improve the health of the populationAssure access to medical careAchieve efficient use of health care resourcesThey are doing what doctors want to do!
-
The key to the need to understand economics - Money doesnt always buy lifeLife expectancy at birth and health spendWHO. The World Health Report 20003 fold variation
-
The key to the need to understand economics - Money doesnt always buy health Relationship between spend and health is not always clear Disability-adjusted life expectancy relative to health expenditure per capita in USD in 191 WHO Member States, 1999WHO. The World Health Report 2000, p43US Dollars>10 fold variation
-
Cost constraints in cancer treatment:What can nations do?
-
We must accept that ration will occurRationing occurs either.by societys willingness to payby personal ability to pay
USA - one in five families used up all of their savings paying for cancer treatment
Cavallo J. The ASCO Post, February 15, 2011, Volume 2, Issue 3
-
European countries - with formal cost-effectiveness approvalAdapted and modified from Zentner et al, 2005societys willingness to pay is crucial to understand when setting priorities for a universal tax-funded or insurance based health serviceThe UK is not alone in wanting to control costs through formal state mechanisms
*****************